Natera (NASDAQ:NTRA) Reaches New 1-Year High - Time to Buy?
Natera (NASDAQ: NTRA) recently reached a new 52-week high, trading around $331, driven by positive analyst sentiment and exceeding quarterly revenue and EPS expectations. While the company remains unprofitable and insiders have sold a significant amount of stock, institutional investors have increased their holdings. Analysts maintain a "Moderate Buy" rating with an average price target of $319.38.
Natera stock reaches all-time high at 326.26 USD
Natera Inc.'s stock has hit an all-time high of $326.26, reflecting a 1-year total return of 102% and a market capitalization of $46.86 billion. This surge follows strong Q2 2026 financial results, with revenue exceeding expectations at $753 million, driven by accelerated growth and increased full-year guidance. Despite the positive performance, InvestingPro analysis suggests the stock is currently overvalued.
Mitsubishi UFJ Asset Management Co. Ltd. Takes $50.42 Million Position in Natera, Inc. $NTRA
Mitsubishi UFJ Asset Management Co. Ltd. has acquired a new stake in Natera, Inc. (NASDAQ:NTRA) worth approximately $50.42 million during the second quarter. This move makes them a significant institutional investor in the medical research company. The article also details other institutional investments, Natera's recent financial performance, analyst ratings, and insider trading activities.
Edmond DE Rothschild Holding S.A. Takes Position in Natera, Inc. $NTRA
Edmond DE Rothschild Holding S.A. has acquired a new stake in Natera, Inc. (NASDAQ:NTRA), purchasing 13,500 shares valued at approximately $3.665 million during the second quarter. This move comes as institutional investors now own 99.90% of Natera's stock, and analysts maintain a "Moderate Buy" rating with an average price target of $319.38, despite significant insider selling totaling $41.3 million over the past 90 days. Natera recently reported strong Q2 revenues of $752.75 million, a 37.7% year-over-year increase, and beat EPS expectations.
Eagle Health Investments LP Makes New Investment in Natera, Inc. $NTRA
Eagle Health Investments LP has initiated a new position in Natera, Inc. by purchasing 15,847 shares valued at approximately $4.3 million. This investment positions Natera as the 23rd largest holding in Eagle Health's portfolio. The news comes as institutional investors collectively own 99.9% of Natera's outstanding stock, and analysts have raised price targets, with a consensus rating of "Moderate Buy" and an average target of $319.38.
BlackRock Inc. Buys Shares of 10,914,608 Natera, Inc. $NTRA
BlackRock Inc. has acquired 10,914,608 shares of Natera, Inc. (NASDAQ:NTRA) during the second quarter, representing a 7.62% stake valued at approximately $2.96 billion. This purchase contributes to the significant institutional ownership of Natera, with 99.90% of the stock held by institutional investors and hedge funds. The company recently reported strong quarterly results, exceeding analyst expectations for both revenue and earnings per share, despite some insider selling activity.
K.J. Harrison & Partners Inc Buys Shares of 18,850 Natera, Inc. $NTRA
K.J. Harrison & Partners Inc recently acquired 18,850 shares of Natera, Inc. (NASDAQ:NTRA) valued at approximately $5.1 million in the second quarter. Institutional investors now own 99.90% of the company, which maintains a "Moderate Buy" consensus rating with an average target price of $319.38. Natera exceeded Q2 earnings expectations, reporting revenue of $752.75 million and an adjusted loss of $0.47 per share, outperforming analyst estimates.
How Investors May Respond To Natera (NTRA) Deepening Its MRD Role In Immunotherapy And Cancer Care
Natera (NTRA) has deepened its role in immunotherapy and cancer care through a collaboration with Kupando Therapeutics for its Latitude tissue-free MRD assay and reported strong Q2 2026 financial results with raised revenue guidance. These developments, alongside expanded use of MRD testing in oncology trials, are embedding Natera's technology further into cancer treatment pathways. While the company still faces high R&D and SG&A costs, these advancements are expected to reshape its investment narrative and growth prospects.
Pallas Capital Advisors LLC Buys Shares of 9,853 Natera, Inc. $NTRA
Pallas Capital Advisors LLC has acquired 9,853 shares of Natera, Inc. (NASDAQ: NTRA) for approximately $2.7 million in the second quarter, making institutional investors now own 99.90% of the company. Natera reported strong quarterly results with revenue up 37.7% year-over-year and adjusted EPS beating estimates. Analysts maintain a "Moderate Buy" rating with an average price target of $319.38.
Weekly Recap: FIND-CRC progress and analyst price target increases
Natera, Inc. (NASDAQ:NTRA) is advancing its early cancer detection efforts through the large FIND-CRC study and a phased commercial rollout. While these initiatives contribute to increased R&D and commercial spending, leading to near-term losses, analysts have responded by raising price targets for the company. Citigroup, Guggenheim, Piper Sandler, and Stephens all increased their price targets, maintaining buy or overweight stances on NTRA.
Empowered Funds LLC Sells 9,708 Shares of Natera, Inc. $NTRA
Empowered Funds LLC reduced its stake in Natera, Inc. (NASDAQ:NTRA) by 65.9% in the first quarter, selling 9,708 shares and retaining 5,016 shares valued at approximately $1.0 million. The medical research company reported strong quarterly revenue of $752.75 million, surpassing analyst expectations, and a narrower-than-expected adjusted loss of $0.47 per share. Analysts generally maintain a "Moderate Buy" rating for Natera with an average price target of $319.38, while the stock currently trades near its 52-week high.
Abbot Financial Management Inc. Takes Position in Natera, Inc. $NTRA
Abbot Financial Management Inc. initiated a new position in Natera, Inc. (NASDAQ:NTRA) during the second quarter, purchasing 5,663 shares valued at approximately $1.54 million. Institutional investors now own 99.90% of Natera's stock, and analysts maintain a "Moderate Buy" rating with an average price target of $319.38. Despite positive analyst sentiment and exceeding revenue estimates, Natera remains unprofitable, reporting a negative net margin and return on equity.
Natera executive chairman Matthew Rabinowitz sells $641,800 stock
Matthew Rabinowitz, Executive Chairman of Natera, Inc., sold 2,000 shares of company stock for $641,800 on August 7, 2026, at $320.9 per share. This sale was conducted under a Rule 10b5-1 trading plan adopted in December 2025. Despite a 90% surge in Natera shares over the past year, InvestingPro analysis indicates the stock is currently overvalued, though the company recently reported second-quarter revenue significantly surpassing expectations.
Net debt of Natera, Inc. – HAM:45E
This article focuses on the net debt of Natera, Inc. (HAM:45E) as listed on the Hamburg Stock Exchange. It indicates that no trades have occurred, and the market is currently closed. The page is part of a financial platform offering various market data and analytical tools.
Natera Spotlights Record Signatera Volumes, Raises Outlook at Canaccord Conference
Natera (NASDAQ: NTRA) reported record Signatera volumes and strong financial performance in Q2, leading the company to raise its financial outlook. The growth was broad-based across its women's health, oncology, and organ health businesses, driven by clinical data, regulatory milestones, and commercial expansion. Natera is also heavily investing in early cancer detection and expanding its laboratory capacity.
Natera director Jonathan Sheena sells $2.89m in stock By Investing.com
Jonathan Sheena, a co-founder and director of Natera, Inc. (NASDAQ: NTRA), recently sold 9,150 shares of company stock for approximately $2.89 million. These sales, executed under a Rule 10b5-1 trading plan, occurred when the stock was near its 52-week high after significant gains. Despite the sales, Natera recently surpassed Wall Street revenue expectations and raised its full-year guidance, although InvestingPro considers the stock currently overvalued.
Leeward Financial Partners LLC Invests $5.31 Million in Natera, Inc. $NTRA
Leeward Financial Partners LLC has invested $5.31 million in Natera, Inc. ($NTRA) during the second quarter of 2026, making Natera its 19th largest holding. Natera reported strong quarterly revenue of $752.75 million, surpassing analyst expectations, and a narrower-than-expected adjusted loss per share. Despite positive analyst sentiment with a "Moderate Buy" rating, company insiders have sold approximately $41.3 million worth of shares in the last 90 days.
GSA Capital Partners LLP Invests $3.08 Million in Natera, Inc. $NTRA
GSA Capital Partners LLP has invested $3.08 million in Natera, Inc. (NTRA) by purchasing 11,336 shares in the second quarter. Natera reported strong quarterly revenue of $752.75 million, surpassing estimates, and institutional investors now collectively own 99.90% of the company. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $319.38, trading near its 12-month high.
Natera director Jonathan Sheena sells $1.95m in common stock
Jonathan Sheena, a director at Natera, Inc. (NASDAQ:NTRA), sold 6,000 shares of common stock totaling approximately $1.95 million on August 10, 2026. This sale was conducted under a Rule 10b5-1 trading plan. Despite the stock surging 90% over the past year, InvestingPro analysis indicates it may be overvalued, while the company recently reported strong Q2 revenue and raised its full-year guidance.
T. Rowe Price Associates (NTRA) discloses 9.0M-share Natera stake in updated 13G
T. Rowe Price Associates has reported an updated 6.3% beneficial ownership stake in Natera, Inc. (NTRA) through an amended Schedule 13G filing. The investment firm now holds 9,021,825 shares, with sole voting power over 8,605,302 shares and sole dispositive power over all 9,021,825 shares. T. Rowe Price Associates explicitly denies beneficial ownership of these securities, stating the filing should not be construed as an admission of such.
Natera (NTRA) Stock Looks Reasonable On Cash Flow But Rich On Sales
Natera (NTRA) stock shows a mixed valuation, with its Discounted Cash Flow (DCF) model indicating it is undervalued by 48.7%, while its Price-to-Sales (P/S) ratio suggests it is expensive compared to industry averages. The DCF model is optimistic due to strong revenue and test volumes, projecting an intrinsic value of $606 per share. However, the P/S ratio of 16.5x, significantly above the biotech industry average, implies investors are already paying a premium for its revenue, reflecting a tension between long-term cash flow potential and high current market expectations.
NATERA, INC. : GUGGENHEIM RAISES TARGET PRICE TO $360 FROM $290
Guggenheim has raised its target price for Natera, Inc. (NTRA) to $360 from $290, indicating a significant increase in the firm's valuation outlook for the company. This news, reported by Reuters, suggests a positive sentiment from Guggenheim regarding Natera's future performance. The specific reasons for the upgrade are not detailed in this short announcement.
NTRA Maintained by Guggenheim -- Price Target Raised to $360
Guggenheim has reiterated its Buy rating for Natera (NTRA) and increased its price target from $290 to $360, signaling strong confidence in the company's future. Despite this positive analyst outlook and Natera's high GF Score™ of 77/100, indicating strong growth and momentum, the stock is considered significantly overvalued by the GF Value™ metric. Investors should also note the lack of insider buying and substantial insider selling, which could complicate the investment thesis despite positive institutional sentiment.
Natera partners with Kupando for phase 1 cancer trial in Germany
Natera Inc. has announced a collaboration with Kupando Therapeutics for a Phase 1 clinical trial in Germany for KUP-101, an investigational immunotherapy for advanced tumors. Natera's Latitude tissue-free assay will be used to monitor treatment response by assessing circulating tumor DNA dynamics. The trial has begun enrolling additional patients across clinical sites in Germany after the first patient was dosed.
First Patient Dosed as Trial Tests Immunotherapy in Skin Cancers
Natera, a leader in cell-free DNA, is collaborating with Kupando Therapeutics on a Phase 1 clinical trial for KUP-101, an immunotherapy for advanced skin cancers. Natera's Latitude MRD test will monitor treatment response by assessing ctDNA dynamics. The first patient has been dosed, and enrollment is ongoing at oncology centers in Germany.
A Natera Insider's Shares Vested Before the Firm Reported Revenue Surged 38%. Here's How to Read It
Natera's CFO, Michael Burkes Brophy, sold 795 shares worth $216,000 just before the company reported a 38% revenue surge. This transaction was not a discretionary sale but a non-discretionary "sell-to-cover" to meet tax obligations from vested equity awards under a Rule 10b5-1 trading plan. The timing suggests it was not an attempt to front-run the earnings report, as Brophy retained a substantial stake, and Natera subsequently reported strong financial results.
A Natera Co-Founder Sold Into Record Highs. Here's What Long-Term Investors Should Know
A co-founder of Natera, Jonathan Sheena, sold 9,150 shares worth $2.9 million, an action executed under a pre-established trading plan set in December 2025. This sale occurred as Natera's stock reached record highs, following a 128% one-year return and strong Q2 revenue growth driven by its Signatera cancer-detection test. Despite the sale, Sheena retains a significant stake, and the transaction is viewed as a planned diversification rather than a negative signal about the company's prospects.
Should You Worry That a Natera Co-Founder Sold Shares? Here's What Long-Term Investors Should Know
Natera co-founder Matthew Rabinowitz sold 731 shares to cover tax obligations from vested restricted stock units, an action dictated by a pre-established plan rather than a discretionary investment decision. This sale represents a negligible fraction of his substantial holdings, valued at over $616 million. The company recently reported strong Q2 revenue growth and raised its full-year outlook, indicating robust operational performance despite this minor insider transaction.
Should You Worry That a Natera Co-Founder Sold Shares? Here's What Long-Term Investors Should Know
Matthew Rabinowitz, co-founder and executive chairman of Natera, Inc. (NASDAQ: NTRA), sold 731 shares worth approximately $195,901 on August 3. This sale was a non-discretionary transaction to cover tax obligations from vested restricted stock units, not a change in his investment outlook. Rabinowitz still retains a substantial stake in Natera, valued at around $616.26 million, and the company recently reported strong financial results.
A Natera Co-Founder Sold Into Record Highs. Here's What Long-Term Investors Should Know
Natera co-founder Jonathan Sheena sold 9,150 shares for approximately $2.9 million through a pre-established trading plan, reducing his equity by 3%. Despite the sale, Sheena retains a significant stake worth $81.97 million, and the company has shown strong performance with 128% one-year total return and increased revenue. The sale is attributed to a pre-scheduled diversification plan rather than a negative outlook on the company, which continues to grow in the molecular diagnostics sector.
US$317 - That's What Analysts Think Natera, Inc. (NASDAQ:NTRA) Is Worth After These Results
This article discusses the average analyst price target for Natera, Inc. (NASDAQ:NTRA) after its recent earnings results. It highlights that the consensus among analysts is a target price of US$317, suggesting a potential upside from its current trading price. The piece likely delves into the factors influencing this valuation and how the latest results might have impacted analyst sentiment.
Natera Stock Jumps As Q2 Beat Triggers Target Hikes
Natera Inc. (NASDAQ: NTRA) shares jumped over 21% following a significant Q2 earnings beat, exceeding revenue expectations and raising full-year guidance for 2026. The company's strong performance was driven by record testing volumes and growth in oncology, leading several major banks to increase price targets and maintain bullish ratings. Natera also submitted its Signatera assay for bladder cancer use in Japan, adding another potential growth catalyst.
Natera, Inc. Stock 12‑Month Price Target Raised to $317.33, Implies 20% Upside
Analysts have increased the average 12-month price target for Natera, Inc. (NTRA) stock from $283.81 to $317.33, with forecasts ranging from $193 to $375 per share. This new target suggests a potential upside of approximately 20% based on the recent closing price. The consensus rating for Natera, Inc. remains a "Buy" among 24 analysts.
Natera, Inc. 2026: Revenue $752.75M, EPS ($0.47) — 10-Q Summary
Natera, Inc. (NTRA) reported its 2026 financial results, showing a significant revenue increase to $752.75 million for the quarter, up 37.7% year-over-year. The company posted a net loss of ($66.97 million) and a diluted loss per share of ($0.47), which represents an improvement compared to the prior year. Revenue growth was driven by higher test volumes and increased average selling prices, with total six-month revenues reaching approximately $1.449 billion.
Key facts: Natera, Inc. Q2 revenue $752.8M; JP Morgan raises PT to $360
Natera (NTRA) reported strong Q2 results with revenue of $752.8M, a 37.7% year-over-year increase, and a record 1.04M tests processed. Following these results, JP Morgan raised its price target for Natera from $315.00 to $360.00 per share, reflecting a revised outlook for the stock. Natera also raised its FY26 revenue guidance to $2.85–2.91B, leading to a 21% increase in shares.
Natera, Inc. Stock 12‑Month Price Target Raised to $317.33, Implies 20% Upside
Analysts have raised the average 12-month price target for Natera, Inc. (NTRA) stock to $317.33, up from $283.81, with a potential upside of approximately 20% based on its August 6 closing price. This new target is based on estimates from 21 analysts, with forecasts ranging from $193 to $375 per share. The consensus rating for NTRA remains a "Buy" from 24 analysts, including 21 Buys and 3 Holds.
Natera director Jonathan Sheena sells $2.89m in stock
Jonathan Sheena, a director and co-founder of Natera, Inc. (NASDAQ:NTRA), sold 9,150 shares for $2.89 million on August 7, 2026, as the stock approaches its 52-week high. These transactions were executed under a Rule 10b5-1 trading plan. The sale follows Natera's strong second-quarter revenue report, which exceeded expectations, and a raised full-year revenue guidance.
Natera, Inc. (NTRA) chair logs 2,000-share sale via 10b5-1 plan
Natera, Inc.'s executive chairman, Matthew Rabinowitz, sold 2,000 shares of common stock on August 7, 2026, at $320.90 per share. This transaction was conducted under a pre-adopted Rule 10b5-1 trading plan from December 5, 2025. Following the sale, Rabinowitz directly holds 2,275,394 shares and indirectly holds 2,000 shares through his spouse.
Natera, Inc. (NTRA) co-founder Jonathan Sheena sells 9,150 shares
Natera, Inc. co-founder and director Jonathan Sheena sold a total of 9,150 shares of common stock on August 7, 2026, through open-market transactions. These sales were executed under a Rule 10b5-1 trading plan adopted in December 2025, with prices ranging from $308.4000 to $320.9000 per share. Following these transactions, Sheena still holds 236,464 direct shares and 18,032 indirect shares in each of the Caraluna 1 and Caraluna 2 Trusts, disclaiming beneficial ownership of the trust-held shares.
Natera, Doximity, PubMatic, Airbnb And Other Big Stocks Moving Higher On Friday
Several major stocks, including Natera, Doximity, PubMatic, and Airbnb, saw significant gains on Friday due to better-than-expected quarterly financial results and raised sales guidance. Natera jumped 20.5% after beating loss estimates and exceeding revenue expectations. Doximity climbed 39%, while Airbnb rose 15.8% after both companies also reported strong financial performance.
Natera Stock Surges After Q2 Earnings Beat And Guidance Hike
Natera (NTRA) saw its stock surge over 21% following a Q2 earnings beat and a raised full-year 2026 revenue guidance. The company reported Q2 revenue of $752.8M, exceeding consensus, and narrowed its per-share loss. Natera also expanded its oncology pipeline with a Signatera test submission for bladder cancer in Japan, signaling strong growth and market confidence.
NTRA Stock Surges After Big Earnings Beat And Guidance Hike
Natera Inc. (NTRA) saw its stock surge over 18% after reporting strong Q2 earnings, beating revenue estimates significantly, and raising its full-year 2026 guidance. The company's Q2 revenue reached $752.8M, far exceeding the $661.2M consensus, while its loss per share of $0.47 was slightly better than expected. Natera also announced the submission of its Signatera minimal residual disease test for approval in Japan, further expanding its global oncology diagnostics platform.
Natera (NASDAQ: NTRA) holder Jonathan Sheena plans 18,000-share stock sale
Jonathan Sheena, a holder of Natera (NASDAQ: NTRA), has filed to sell 18,000 common shares with an aggregate value of $5,951,100.00. These shares are related to ISO stock options dated March 9, 2022, and will be sold via Charles Schwab & Co., Inc. on NASDAQ. The filing also details previous sales by Sheena between May and August 2026, ranging from 109 to 3,150 shares.
Natera Reports Second Quarter 2026 Financial Results
Natera, Inc. announced strong financial results for the second quarter of 2026, with total revenues reaching $752.8 million, a 37.7% increase year-over-year. The company also processed over 1 million tests and saw significant growth in oncology test volumes. Natera raised its 2026 annual revenue guidance to $2.85 billion - $2.91 billion, reflecting continued momentum in its cell-free DNA and genetic testing services.
Natera Inc (NTRA) (Q2 2026) Earnings Call Highlights: Record Volumes and Raised Guidance Signal ...
Natera Inc. (NTRA) reported record Q2 2026 results, including approximately $753 million in total revenue and 1,044,000 tests processed, leading to a raised revenue guidance for fiscal 2026. The company highlighted significant growth in oncology volumes, improved gross margins, and strategic advancements in its early cancer detection program and women's health portfolio. Despite competitive pressures and elevated R&D spending, Natera expects continued growth driven by physician adoption of MRD testing and future MolDX coverage expansions.
Natera Inc earnings beat by $0.02, revenue topped estimates
Natera Inc (NASDAQ: NTRA) reported strong second-quarter results, beating analyst EPS estimates by $0.0
Natera, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:NTRA)
Natera, Inc. (NTRA) released its Q2 2026 earnings, reporting an EPS of -$0.47, which beat estimates by $0.06. The company's revenue for the quarter reached $752.75 million, surpassing expectations by $91.46 million and representing a 37.71% year-over-year increase. This article includes the slide deck presented during their earnings call.
Natera president John Fesko sells $79,056 in company stock.
Natera's President and Chief Business Officer, John Fesko, sold 295 shares of the company's stock worth $79,056 to cover tax obligations related to vested restricted stock units. The sale occurred while Natera's stock is near its 52-week high and has shown a 99% return over the past year, though InvestingPro analysis suggests it may be overvalued. Natera has also recently achieved IVDR certification for its Signatera test, published positive data in JAMA Oncology, and entered a new partnership and analyst coverage.
Form 4 Natera Inc For: 6 August By Investing.com
This article reports on a Form 4 filing for Natera Inc. on August 6th. It mentions the company's stock symbol NTRA, which experienced a -3.65% change, and invites readers to view comments. The content is very brief and mostly consists of navigation and market data.
Natera president Solomon Moshkevich sells $905,626 in stock
Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold 3,410 shares of company stock worth $905,626 on August 3, 2026, with prices ranging from $259.98 to $268.6964 per share. These sales included shares to cover tax obligations from vested RSUs and shares sold under a Rule 10b5-1 trading plan. Following the transactions, Moshkevich beneficially owns 129,019 shares of Natera common stock, as the company's shares trade near their 52-week high after a significant 99% return over the past year.
